Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma
This study is currently recruiting participants.
Verified by Fondazione Intergruppo Italiano Linfomi Onlus, October 2008
Sponsored by: Fondazione Intergruppo Italiano Linfomi Onlus
Information provided by: Fondazione Intergruppo Italiano Linfomi Onlus
ClinicalTrials.gov Identifier: NCT00774826
  Purpose

The purpose of this study is to define an improvement and theassessment of the Time to Treatment Failure in patients randomized in three different arms:

R−CVP vs R−CHOP vs R−FM.


Condition Intervention Phase
Follicular Lymphoma
 Drug: R-CVP
Drug: R-CHOP
Drug: R-FM
 Phase III

MedlinePlus related topics: Lymphoma
Drug Information available for: Cyclophosphamide Mitoxantrone hydrochloride Mitoxantrone Prednisone Rituximab
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title: Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma

Further study details as provided by Fondazione Intergruppo Italiano Linfomi Onlus:

Primary Outcome Measures:
  • Assessment of the Time to Treatment Failure (TTF)in patients treated with R-CVP, R-CHOP and R-FM. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Assessment of Overall Survival (OS)in patients treated with R−CVP, R−CHOP and R−FM. − [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • Assessment of Progression Free Survival (PFS)in patients treated with R-CVP, R-CHOP [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Assessment of Duration of Response (DR)in patients treated with R-CVP, R-CHOP and R-FM. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Assessment of Response Rate(RR) in patients treated with R-CVP, R-CHOP and R-FM. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Assessment of molecular Response Rate in patients treated with R-CVP, R-CHOP and R-FM. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • Assessment of toxicity of R-CVP, R-CHOP, R-FM treatments. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 431
Study Start Date: December 2005
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
R-CVP x 3; Restaging if> RP then R-CVP x 5
Drug: R-CVP
Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
2: Experimental
R-CHOP x 3; Restaging if > RP then R-CHOP x 3 plus 2 Rituximab
Drug: R-CHOP
Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
3: Experimental
R-FM x 3; Restaging if > RP then R-FM x 3 plus 2 Rituximab
Drug: R-FM
Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,

Detailed Description:

Assessment of Overall Survival (OS)in patients treated with R−CVP, R−CHOP and R−FM. −Assessment of Progression Free Survival (PFS)in patients treated with R−CVP, R−CHOP − Assessment of Duration of Response (DR)in patients treated with R−CVP, R−CHOP and R−FM. − Assessment of Response Rate(RR) in patients treated with R−CVP, R−CHOP and R−FM. − Assessment of molecular Response Rate in patients treated with R−CVP, R−CHOP and R−FM. − Assessment of toxicity of R−CVP, R−CHOP, R−FM treatments.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histological DIAGNOSIS of B cell follicular lymphoma
  2. ECOG performance status 0−2
  3. Age range 18−75
  4. Ann Arbor Stage: II−IV
  5. Assessment of pathology with diagnostics biopsy

  6. Presence of one of these criteria:

    • B Sistemic symptoms B
    • Extranodale pathology
    • Cytopenia
    • Splenomegaly
    • Leukemia
    • Serous effusion
    • Ves > 20 mm/h
    • Ldh > normal value
    • Nodale or extranodal mass > 7 cm
    • 3 or more nodal sites > 3 cm
    • Adenopatic syndrome
  7. LVEF > 50%
  8. Normal hepatic (bilirubin < 1.5 mg/dl) and renal functionality (creatinin < 2 mg/dl). If there is a lymphoma it's allow values of bilirubin > 1.5 mg/dl and of creatinin > 2mg/dl
  9. No previous treatment for follicolar lymphoma unless RT−IF
  10. Lifetime > 6 mounth
  11. Absence of HbsAg, HCV e HIV
  12. Negative Coombs Test
  13. Negative pregnant test
  14. Cotracceptive method during the treatment and the follow three months
  15. Formal written consent
  16. Ability to follow the patients after the treatment for follow up

Exclusion Criteria:

  1. Histological Diagnosis of all type of lymphoma unless Follicularlymphoma, CD20 lymphoma, stage IIIb of follicular lymphoma and high degree lymphoma
  2. Stage I of Ann Arbor scale
  3. Central Nervous system involvement
  4. HIV, HBV OR HCV Positivity
  5. Cardiac Pathology
  6. Positive Coombs Test
  7. Previous chemotherapeutic treatment
  8. Hypersensitivity to antibodyes or other murine proteins
  9. Previous cancer pathology unless in situ cervix and epithelial carcinomas
  10. Other type of infections
  11. Pregnant and nursing woman
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00774826

Contacts
Contact: Sonia Perticone, PhD 00390131206129 segreteria@iilinf.it

  Show 79 Study Locations
Sponsors and Collaborators
Fondazione Intergruppo Italiano Linfomi Onlus
Investigators
Principal Investigator: Massimo Federico, PhD Azienda Ospedaliera - Universitaria di Modena
  More Information

Responsible Party: AZIENDA OSPEDALIERA POLICLINICO - MODENA (MO) ( MASSIMO FEDERICO )
Study ID Numbers: IIL−FOLL05, Eudract Number 2005−005406−24
Study First Received: October 14, 2008
Last Updated: October 23, 2008
ClinicalTrials.gov Identifier: NCT00774826  
Health Authority: Italy: National Monitoring Centre for Clinical Trials - Ministry of Health

Keywords provided by Fondazione Intergruppo Italiano Linfomi Onlus:
Follicular lymphoma
Rituximab

Study placed in the following topic categories:
Prednisone
Lymphatic Diseases
Immunoproliferative Disorders
Rituximab
Lymphoma, Follicular
Mitoxantrone
 Cyclophosphamide
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Lymphoma
Follicular lymphoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services